The number of Brazilian women living with HIV has increased significantly in past years, rendering studies of their particular care demands including psychiatric issues. This study measures the prevalence of major depression, using the Structured Clinical Interview for DSM-IV Axis I Disorders, in a sample of 120 women living with HIV in treatment at a reference centre in São Paulo. Socio-demographic variables, HIV-related clinical and laboratory data, including CD4+ cell counts and HIV plasma viral loads, as well as psychosocial features (intimate relationships, disclosure of HIV serostatus, partner's serostatus and patient's emotional and financial support) were investigated as factors potentially associated with depression. The prevalence of major depression at the time of evaluation was 25.8% (95% CI 18.2-33.4%). Clinical status (p = 0.002), lack of emotional support (p = 0.02), use of antidepressants (p = 0.028) and length of time since HIV diagnosis (p = 0.05) were associated with major depression in univariate analysis. In multivariate multiple-regression model, HIV clinical status, lack of emotional support and higher plasma viral loads were associated with depression. Sixty per cent of the women have a major depression diagnosis during lifetime. We conclude that major depression is highly prevalent among women living with HIV, but it is still underdiagnosed and undertreated.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00737-009-0094-1 | DOI Listing |
Fam Process
March 2025
Unit of Psychiatry, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Borderline personality disorder (BPD) has a strong impact not only on patients' lives but also on their families. The presence of an invalidating environment is one of the key factors in the etiology of BPD. This study evaluated the impact of the Family connections (FC) program on burden, grief, and other clinical variables in 202 caregivers and identified the profiles of participants who improved/deteriorated their levels of burden and grief.
View Article and Find Full Text PDFClin Pract Epidemiol Ment Health
December 2024
Department of Family and Community Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Background: Obsessive-compulsive disorder is recognized by the World Health Organization as one of the top 10 most disabling disorders globally. Characterized by recurrent and persistent thoughts (obsessions) and/or repetitive behaviors (compulsions), it significantly disrupts an individual's daily life, impacting routine, education, career development, and social relationships. The disorder's prevalence varies worldwide, with studies in Saudi Arabia showing a higher rate of obsessive-compulsive symptoms among medical students.
View Article and Find Full Text PDFCureus
December 2024
Department of Psychiatry, Tokyo Women's Medical University, Tokyo, JPN.
Introduction Psychoeducation is a form of psychosocial treatment with proven efficacy in preventing the relapse of bipolar disorder (BD). However, the effectiveness of psychoeducation has not been verified in Japan. We aimed to examine the effect of a brief group psychoeducation course (eight-session long) on relapse prevention in Japanese patients with BD and associated factors.
View Article and Find Full Text PDFFront Psychiatry
January 2025
Feneryolu Medical Center, Üsküdar University, Istanbul, Türkiye.
Introduction: Major Depressive Disorder (MDD) leads to dysfunction and impairment in neurological structures and cognitive functions. Despite extensive research, the pathophysiological mechanisms and effects of MDD on the brain remain unclear. This study aims to assess the impact of MDD on brain activity using EEG power spectral analysis and asymmetry metrics.
View Article and Find Full Text PDFAnn Gen Psychiatry
January 2025
AbbVie, North Chicago, IL, USA.
Background: Atypical antipsychotics are a common treatment for serious mental illness, but many are associated with adverse effects, including weight gain and cardiovascular issues, and real-world experience may differ from clinical trial data. Cariprazine has previously demonstrated a favorable safety and tolerability profile in clinical trials. Here, we evaluated the effects of cariprazine on body weight and blood pressure for bipolar I disorder (BP-I), schizophrenia, or as adjunctive treatment for major depressive disorder (MDD) using real-world data.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!